Decentralized Trials
Traditional clinical trial designs were dependent upon subject visits to a healthcare or research facility for assessment. Decentralized clinical trials (DCTs) minimize such in-clinic visits through the use of telemedicine, electronic tools, remote assessment and wearable devices to collect data. One way to conceptualize this is that traditional study designs demanded that patients participated in clinical trials by going to clinics, while DCTs enable the “clinic” to go to the patients. The advantages of DCTs, enabled by currently available technologies, are substantial. We are now able to meet the patients where they are, in naturalistic settings, minimizing the burden of study participation. Former concerns about data integrity have been replaced by an awareness that high quality data can be collected remotely, and in greater volume, than ever before possible in traditional study designs. Not only are we able to meet the patients where they are, we also can now meet the physician investigators where they are, given that telemedicine has gained widespread use.
Clinilabs conducts DCTs using “best in class” technology tools from our in-house data systems and from 3rd party vendors. We are differentiated from other CROs in that we are experts in identifying the right tools for the right jobs, and we are able to ensure interoperability of data systems. Such full integration creates a bundled value when conducting DCTs.
Click below to learn how Clinilabs’ designed a decentralized trial at the onset of the COVID-19 pandemic.
The cures we want aren’t going to fall from the sky. We have to get ladders and climb up and get them.
The reward for work well done is the opportunity to do more.
All truths are easy to understand once they are discovered; the point is to discover them.
One sometimes finds what one is not looking for.
If you think compliance is expensive, try non-compliance.
Advances in drug development have led to greater improvement in the quality of human life than advances in all other fields combined.
Remember the Three Princes of Serendip who went out looking for treasure? They didn’t find what they were looking for, but they kept finding things just as valuable. That’s serendipity, and our business [drugs] is full of it.
Without drugs, physicians would struggle to find relevance, and patients would suffer without hope.
The pace of discovery is going unbelievably fast.
Good information is the best medicine.
I trust I may be enabled in the treatment of patients always to act with a single eye to their good.
There is so much more to be done; the patients are waiting.
Let me tell you the secret that has led me to my goal. My strength lies solely in my tenacity.
It is easy to get a thousand prescriptions, but hard to get one single remedy.
One never notices what has been done; one can only see what remains to be done.
The greatest joy in life is to accomplish. It is the getting, not the having. It is the giving, not the keeping.
I have no ideology. My ideology is health.
The best way to predict the future is to invent it.
Drugs don’t work in patients who don’t take them.
I am not accustomed to saying anything with certainty after only one or two observations.
I must say, I spend a lot of my time these days trying to persuade people that controlled trials are the only way to get information that’s reliable about drugs.